| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
37,470,000 |
| Market
Cap: |
116.53(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.73 - $9.27 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Voyager Therapeutics is a gene therapy company focused on developing treatments and platform technologies. Co.'s team has developed a proprietary adeno-associated virus (AAV) capsid discovery platform called TRACER™ (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) to facilitate the selection of AAV capsids with blood brain barrier crossing and cell-specific transduction properties for particular therapeutic applications. The TRACER discovery platform is a functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
20,971 |
77,515 |
90,014 |
166,592 |
| Total Sell Value |
$71,931 |
$322,474 |
$394,113 |
$1,035,821 |
| Total People Sold |
2 |
5 |
5 |
6 |
| Total Sell Transactions |
2 |
11 |
13 |
26 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ferguson Toby |
Chief Medical Officer |
• – – |
2025-04-02 |
4 |
S |
$3.43 |
$34,595 |
D/D |
(10,086) |
157,914 |
|
13% |
|
| Sandrock Alfred |
President and CEO |
• • – |
2025-04-02 |
4 |
S |
$3.43 |
$37,336 |
D/D |
(10,885) |
430,931 |
|
13% |
|
| Fahey Sandell Jacquelyn |
Chief Legal Officer |
• – – |
2025-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
41,500 |
123,143 |
|
- |
|
| Sandrock Alfred |
President and CEO |
• • – |
2025-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
145,000 |
441,816 |
|
- |
|
| Jorgensen Nathan D. |
Chief Financial Officer |
• – – |
2025-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
51,500 |
131,500 |
|
- |
|
| Carter Todd Alfred |
Chief Scientific Officer |
• – – |
2025-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
46,000 |
123,718 |
|
- |
|
| Ferguson Toby |
Chief Medical Officer |
• – – |
2025-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
63,000 |
168,000 |
|
- |
|
| Swartz Robin |
COO & CBO |
• – – |
2025-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
71,250 |
169,647 |
|
- |
|
| Sandrock Alfred |
President and CEO |
• • – |
2025-02-20 |
4 |
S |
$4.24 |
$49,616 |
D/D |
(11,702) |
296,816 |
|
31% |
|
| Carter Todd Alfred |
Chief Scientific Officer |
• – – |
2025-02-20 |
4 |
S |
$4.26 |
$14,079 |
D/D |
(3,305) |
77,718 |
|
31% |
|
| Swartz Robin |
COO & CBO |
• – – |
2025-02-20 |
4 |
S |
$4.25 |
$16,550 |
D/D |
(3,894) |
98,397 |
|
31% |
|
| Sandrock Alfred |
President & CEO |
• – – |
2025-02-11 |
4 |
S |
$4.45 |
$74,066 |
D/D |
(16,644) |
308,518 |
|
30% |
|
| Carter Todd Alfred |
Chief Scientific Officer |
• – – |
2025-02-11 |
4 |
S |
$4.45 |
$24,088 |
D/D |
(5,413) |
81,023 |
|
30% |
|
| Fahey Sandell Jacquelyn |
Chief Legal Officer |
• – – |
2025-02-11 |
4 |
S |
$4.45 |
$19,393 |
D/D |
(4,358) |
81,643 |
|
30% |
|
| Swartz Robin |
COO & CBO |
• – – |
2025-02-11 |
4 |
S |
$4.45 |
$30,928 |
D/D |
(6,950) |
102,291 |
|
30% |
|
| Carter Todd Alfred |
Chief Scientific Officer |
• – – |
2025-01-14 |
4 |
S |
$5.13 |
$6,110 |
D/D |
(1,191) |
86,436 |
|
42% |
|
| Swartz Robin |
COO & CBO |
• – – |
2025-01-14 |
4 |
S |
$5.09 |
$15,713 |
D/D |
(3,087) |
109,241 |
|
42% |
|
| Swartz Robin |
COO&CBO |
• – – |
2024-12-23 |
4 |
S |
$5.65 |
$36,725 |
D/D |
(6,500) |
112,328 |
|
43% |
|
| Fahey Sandell Jacquelyn |
Chief Legal Officer |
• – – |
2024-10-02 |
4 |
S |
$5.82 |
$34,914 |
D/D |
(5,999) |
86,001 |
|
24% |
|
| Jorgensen Nathan D. |
Chief Financial Officer |
• – – |
2024-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
80,000 |
|
- |
|
| Swartz Robin |
Chief Operating Officer |
• – – |
2024-04-02 |
4 |
S |
$9.88 |
$13,407 |
D/D |
(1,357) |
117,004 |
|
33% |
|
| Sandrock Alfred |
President and CEO |
• • – |
2024-04-02 |
4 |
S |
$9.86 |
$119,454 |
D/D |
(12,115) |
322,839 |
|
33% |
|
| Ferguson Toby |
Chief Medical Officer |
• – – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
105,000 |
105,000 |
|
- |
|
| Pfreundschuh Peter P. |
Chief Financial Officer |
• – – |
2024-02-21 |
4 |
S |
$7.46 |
$28,079 |
D/D |
(3,764) |
175,669 |
|
1% |
|
| Sandrock Alfred |
President and CEO |
• • – |
2024-02-21 |
4 |
S |
$7.46 |
$97,226 |
D/D |
(13,033) |
334,954 |
|
1% |
|
182 Records found
|
|
Page 1 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.15 (5.07%) 
